Empagliflozin/Metformin Tablet 12.5/500 mg
Empagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Myungmoon Pharmaceutical Co., Ltd.
MFDS item code 202302723 · Approved 2023.09.12
Improvement of glycemic control in adults with type 2 diabetes mellitus
This drug is used to improve blood sugar control in adult patients with type 2 diabetes mellitus through the combined action of empagliflozin and metformin. It plays a supportive role in dietary and exercise therapy, allowing for more effective management of blood sugar levels. It is particularly administered when blood sugar is not adequately controlled, and patients with cardiovascular disease must verify precautions according to their physician's instructions. This drug helps in controlling blood sugar levels in patients with type 2 diabetes and supports health management.
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose of this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s existing metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from concomitant therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their existing doses of empagliflozin and metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Interactions under Precautions for Use). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated using the individual single-ingredient products of empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see section 3. Use with caution in the following patients, item 1, under Precautions for Use). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see section 2. Do not administer to the following patients, item 2, under Precautions for Use). Elderly patients In patients 75 years of age and older, renal function and the risk of volume depletion should be considered.
This drug can cause a rare but serious condition known as lactic acidosis. Lactic acidosis occurs when there is an excessive accumulation of lactate in the body and can be life-threatening in severe cases. Therefore, this drug should not be used in patients with impaired renal function or severe infections, dehydration, or heart failure. Additionally, caution is required when using this drug together with insulin or sulfonylurea as it may cause hypoglycemia. Regular tests should be conducted to ensure normal renal function while taking this drug, and it should not be used in cases of severely impaired renal function. Before and after tests using iodine contrast agents, this drug should be temporarily discontinued and resumed only after confirming normal renal function. Patients about to undergo surgery should also stop taking this drug 48 hours prior to surgery and can resume after renal function has recovered post-surgery. Women who are pregnant or may become pregnant, and breastfeeding women should not use this drug; particularly during pregnancy, insulin treatment is recommended. If dehydration, severe infections, or acute heart failure occur while taking this drug, it should be stopped immediately and a doctor consulted. This drug may cause side effects such as urinary tract infections, genital infections, increased urination, gastrointestinal disturbances (nausea, vomiting, diarrhea), hypoglycemia, and others. Elderly patients or those at risk of decreased fluid volume should exercise increased caution. Additionally, as vitamin B12 levels may decrease, regular blood tests are advised. The risk of lactic acidosis increases when taken with alcohol, so alcohol should be avoided. Regular meals and exercises should be maintained for blood sugar control while on this drug, and immediate action should be taken if hypoglycemic symptoms appear. Finally, this drug is not recommended for children, and elderly patients may require dosage adjustments based on renal function. In cases of overdose, immediate medical attention is required, and treatment such as dialysis may be necessary if lactic acidosis is suspected.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container to protect it from air and moisture, and it is safe to store it at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness for a longer period.
A film-coated tablet that is oval, convex on both sides, and has a light brownish-purple color.
60 tablets/box[(10 tablets/PTP x 6)], 10 tablets/box[(10 tablets/PTP x 1)], 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Myungmoon Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.